InterMune (nasdaq)ITMN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Secret_Agent_Man who started this subject	10/26/2000 10:49:14 PM
From: IRWIN JAMES FRANKEL	of 508

CHEST I attended the American College of CHEST Physicians in San Francisco to hear the "Managment of Idiopathic Pulmonary Fibrosis by the Practicing Pulmonologist". It was well attended (about425) and very interesting. Dr. Marvin Schwartz indicated that there are 100,000 IPF cases in the US and 5,000,000 worldwide. He also indicated that Actimmune is the best chance to help people with IPF that he has seen in the last 30 years. He also mentioned that he had encouraged Genentech to test the drug on IPF but the idea was not accepted. Dr. David Lynch said, We may be entering the exciting phase where we have a treatment for the disease. (IPF) [I did not use quotation marks since the statement is not verbatim - I don't write that fast - but it should be close.] I hope these guys are right. If so ITMN has a big winner. When data from the Phase III for IPF is released we will know for sure. ij

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next